Search hospitals

>

Ohio

>

Cleveland

MetroHealth Medical Center

Claim this profile

Cleveland, Ohio 44109

Global Leader in Ovarian Cancer

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Stroke

Conducts research for Fallopian Tube Cancer

497 reported clinical trials

29 medical researchers

Photo of MetroHealth Medical Center in ClevelandPhoto of MetroHealth Medical Center in Cleveland

Summary

MetroHealth Medical Center is a medical facility located in Cleveland, Ohio. This center is recognized for care of Ovarian Cancer, Lung Cancer, Breast Cancer, Stroke, Fallopian Tube Cancer and other specialties. MetroHealth Medical Center is involved with conducting 497 clinical trials across 749 conditions. There are 29 research doctors associated with this hospital, such as William T. Tse, Kimberly E. Resnick, Sareena Singh, and Jennifer Bailit, MD.

Area of expertise

1

Ovarian Cancer

Global Leader

MetroHealth Medical Center has run 38 trials for Ovarian Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Lung Cancer

Global Leader

MetroHealth Medical Center has run 37 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV

Top PIs

Clinical Trials running at MetroHealth Medical Center

Breast Cancer

Prostate Cancer

Skin Cancer

Lung Cancer

Non-Small Cell Lung Cancer

Spinal Cord Injury

Multiple Myeloma

Endometrial Cancer

Uterine Cancer

Breast cancer

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at MetroHealth Medical Center?

Where is MetroHealth Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does MetroHealth Medical Center accept?

What awards or recognition has MetroHealth Medical Center received?